$PMCB PharmaCyte Biotech's Pancreatic Cancer Treat
Post# of 72711
Posted On: 01/23/2015 11:36:14 AM
$PMCB PharmaCyte Biotech's Pancreatic Cancer Treatment Named as Near-Term Approach to Rising Pancreatic Cancer Rates
SILVER SPRING, Md., Jan 15, 2015 (GLOBE NEWSWIRE via COMTEX) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.
The article appeared in the December edition of the Journal of the National Cancer Institute prior to the Company's name change from Nuvilex to PharmaCyte Biotech. Brower's article is titled "New Approaches Tackle Rising Pancreatic Cancer Rates" and can be read in full at: http://jnci.oxfordjournals.org/content/106/12/dju417.full.
SILVER SPRING, Md., Jan 15, 2015 (GLOBE NEWSWIRE via COMTEX) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box, today announced that well-known scientific journalist, Vicki Brower, who writes for the leading top-tier cancer journals, has published an article naming PharmaCyte Biotech's pancreatic cancer treatment as a near-term approach to tackling the rising pancreatic cancer rates.
The article appeared in the December edition of the Journal of the National Cancer Institute prior to the Company's name change from Nuvilex to PharmaCyte Biotech. Brower's article is titled "New Approaches Tackle Rising Pancreatic Cancer Rates" and can be read in full at: http://jnci.oxfordjournals.org/content/106/12/dju417.full.
(0)
(0)Scroll down for more posts ▼